Affiliations 

  • 1 Department of Pharmacology, Faculty of Medicine, MAHSA University, Malaysia
  • 2 Department of Pathology, Faculty of Medicine, MAHSA University, Malaysia
  • 3 Depaerment of Biochemistry, Faculty of Medicine, MAHSA University, Malaysia
  • 4 Faculty of Bio-economy and Health Sciences, Geomatika University College Kuala Lumpur, Malaysia
  • 5 Department of Pharmaceutical Chemistry, Faculty of Pharmacy AIMST University, Malaysia
Pak J Pharm Sci, 2020 Jul;33(4):1739-1745.
PMID: 33583811

Abstract

The outbreak of CoVID-19 infection rapidly increases worldwide. Most of the continents affecting from CoVID-19 and still widening its burden disease (Jones DS, 2020; Lai et al., 2020). Along with its fatality rates, CoVID-19 has caused physiological disturbances in the society and termed as "coronophobia". CoVID-19 with renal failure, severe pneumonia and respiratory syndrome patients have been reported to increase the severity of disease conditions (Sevim et al., 2020). Also, CoVID-19 with cancer patients increase the higher risk of infections. Currently, there is no vaccine or specific treatment against CoVID-19 and drug research centres continuously investigating the potential drug against CoVID-19 (Osama and Amer, 2020). For the past 20 years two major coronavirus epidemics have occurred in public includes SARS-CoV approximately 8000 cases and 800 deaths and MERS-CoV 2,500 cases and 800 deaths and these continuing sporadically (Cascella et al., 2020).

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.